ESPERION THERAPEUTICS INC(NASDAQ:ESPR) stock News

ESPR Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Chartmill

Esperion Therapeutics Inc (NASDAQ:ESPR) Beats Q2 2025 Revenue Forecasts and Reduces Losses Amid Strong Prescription Growth

2 days ago - By: Esperion Therapeutics, Inc.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

2 days ago - By: Esperion Therapeutics, Inc.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

3 days ago - By: Zacks Investment Research - Mentions: CRMD ARVN IMCR

ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises

3 days ago - By: The Motley Fool

Esperion (ESPR) Q2 Revenue Jumps 12%

4 days ago - By: Zacks Investment Research - Mentions: NOTV

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

4 days ago - By: Esperion Therapeutics, Inc.

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

4 days ago - By: Esperion Therapeutics, Inc.

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

4 days ago - By: Benzinga - Mentions: AFG CXDO YUM PACK ...

Earnings Scheduled For August 5, 2025

5 days ago - By: Benzinga

What to Expect from Esperion Therapeutics's Earnings

11 days ago - By: Zacks Investment Research - Mentions: BCRX

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

11 days ago - By: Yahoo Finance

Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors

18 days ago - By: Esperion Therapeutics, Inc.

Esperion to Report Second Quarter 2025 Financial Results on August 5

18 days ago - By: Esperion Therapeutics, Inc.

Esperion to Report Second Quarter 2025 Financial Results on August 5

a month ago - By: Esperion Therapeutics, Inc.

Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

a month ago - By: Esperion Therapeutics, Inc.

Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

a month ago - By: Esperion Therapeutics, Inc.

Esperion Appoints Craig Thompson to Board of Directors

a month ago - By: Esperion Therapeutics, Inc.

Esperion Appoints Craig Thompson to Board of Directors

2 months ago - By: Zacks Investment Research - Mentions: IONS

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?

2 months ago - By: Esperion Therapeutics, Inc.

Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

3 months ago - By: Esperion Therapeutics, Inc.

Esperion to Participate in Upcoming June Investor Conferences

3 months ago - By: Esperion Therapeutics, Inc.

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

3 months ago - By: Esperion Therapeutics, Inc.

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

3 months ago - By: Esperion Therapeutics, Inc.

Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference

3 months ago - By: Esperion Therapeutics, Inc.

Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference

3 months ago - By: Esperion Therapeutics, Inc.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

3 months ago - By: Esperion Therapeutics, Inc.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

3 months ago - By: Esperion Therapeutics, Inc.

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

3 months ago - By: Esperion Therapeutics, Inc.

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

3 months ago - By: Zacks Investment Research - Mentions: ANIP NTLA IMCR

ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down

3 months ago - By: Zacks Investment Research - Mentions: MGX

Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates

3 months ago - By: Esperion Therapeutics, Inc.

Esperion Reports First Quarter 2025 Financial Results

3 months ago - By: Esperion Therapeutics, Inc.

Esperion Reports First Quarter 2025 Financial Results

3 months ago - By: Zacks Investment Research - Mentions: COLL

Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?

3 months ago - By: Zacks Investment Research - Mentions: OCUL

ESPERION THERAPEUTICS INC (ESPR) Stock News

ESPR Latest News, Press Relases and Analysis